Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Arra, Aditya, Pech, Maximilian, Fu, Hang, Lingel, Holger, Braun, Franziska, Beyer, Christian, Spiliopoulou, Myra, Bröker, Barbara M., Lampe, Karen, Arens, Christoph, Vogel, Katrin, Pierau, Mandy, Brunner-Weinzierl, Monika C.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8204976/
https://ncbi.nlm.nih.gov/pubmed/34178430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1938475
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados